The IJTLD provides a free-to-publish journal for authors (mainly in LMICs), who lack open access funding and conduct research on respiratory health.
The journal's coverage is distinct to IJTLD Open, which has a broader range of articles and scope. Please compare the Instructions for Authors for the two journals to ensure your article is appropriate for the IJTLD.
Individuals and Institutes can subscribe to the IJTLD online, simply e-mail us at subscription@theunion.org
Information for Authors
The Journal presents clinical research and epidemiological studies on lung health, including articles on TB, TB-HIV and respiratory diseases such as COVID-19, asthma, COPD, child lung health and the hazards of tobacco and air pollution.
Abstract and indexing services include: Medline, PubMed, Scopus, EMBASE, Web of Science, SciSearch®, Medical Documentation Service®, ISI Alerting Services, Current Contents®/Clinical Medicine, the Science Citation Index®, the SIIC databases, CLOCKSS and LOCKSS.
Other Information
- Frequency: monthly
- ISSN: online version 1815-7920
- Permission requests: contact IJTLD Editorial Office.
There are no fees for articles that meet our recommended page lengths, but there are fees for additional pages or supplementary data - see Journal Publication Charges
Funding agencies have recently mandated that authors must publish exclusively in fully-OA journals.
We are committed to maintaining the IJTLD for authors in LMICs who lack OA funding, while also launching a new title, IJTLD OPEN, which covers a broader range of topics with additional article types.
To ensure we apply the same quality standards for open access publishing, both journals have the same Editorial Board with an identical peer review process and acceptance criteria. Before submitting, please check whether your article is better suited to the IJTLD or IJTLD Open.
The latest peer-reviewed articles on TB and HIV; respiratory diseases such as asthma and COPD; and the hazards of tobacco and air pollution. Recent coverage has expended to include COVID-19 and the interplay between TB-COVID-19 and other co-morbidities.
Individuals and institutes can subscribe to the IJTLD online – see our Subscription information or e-mail us at subscription@theunion.org for details.
Advertising or sponsoring content is an effective means of reaching clinicians, researchers, health workers, decision makers and students.
Sponsors can support the creation of a Collection or a Supplement on a relevant topic of interest, either in print or a digital collection of articles, for elevated visibility of your products and services.
Other opportunities include being involved in the creation of informative Posters, Infographics, or scientific Animations to clarify relevant biological processes.
IJTLD Fast-Track Articles
In order to share scientific research of immediate concern as rapidly as possible, The Union is fast-tracking the publication of certain accepted articles from the IJTLD and publishing them in full on our website, prior to their publication in the Journal. Read fast-track articles:
Diagnosis patterns for rifampicin-resistant TB after onset of COVID-19
In this recently accepted article for IJTLD, the authors found that RR-TB diagnosis decreased by 21–38% following the start of the pandemic. The results are disturbing and suggest that COVID-19 has had a sustained impact at a time when household transmission of TB/RR-TB might have increased due to ‘shelter at home’. The preprint is free to read.
Asymptomatic COVID-19 – implications for the control of transmission in South Africa
The authors conducted a retrospective analysis to determine the proportion of asymptomatic COVID-19 in the workplace during lockdown in early 2020. Nearly 45% of cases were asymptomatic, which has implications for interventions, such as enforcing quarantine of all close contacts of COVID-19 cases regardless of symptoms.
Pretomanid with bedaquiline and linezolid for drug-resistant TB: a comparison of prospective cohorts
In this recently accepted article for IJTLD, the authors performed a cohort-comparison study to assess Pretomanid in a regimen to treat drug-resistant TB: patients receiving the BPaL regimen had a significantly better 6-month post-treatment outcome than those on the B–L regimen. The preprint is free to read.
Other versions of the journal
The IJTLD has been published in several languages, and publishes the Union World Conference abstract book each year.
Contact
For all IJTLD enquiries, please contact the IJTLD Editorial Office.